Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
- Clements University Hospital
Larry Anderson, M.D., Ph.D.
A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Phase 1 will be an open-label study. The dose escalation portion of the study is designed to
establish the MTD of ibrutinib in combination with carfilzomib with or without dexamethasone.
Phase 2b will be an open-label, multicenter study designed to evaluate the overall response rate when ibrutinib is administered in combination with carfilzomib and dexamethasone.
Bruton's tyrosine kinase (Btk) is an enzyme that is present in hematopoietic cells other than T cells and is necessary for downstream signal transduction from various hematopoietic receptors including the B cell receptor as well as some Fc, chemokine, and adhesion receptors, and is crucial for both B cell development and osteoclastogenesis. Although down-regulated in normal plasma cells, Btk is highly expressed in the malignant cells from many myeloma patients and some cell lines. PCI-32765 is a potent and specific inhibitor of Btk currently in Phase 2 and 3 clinical trials. The current study is designed and intended to determine the safety and efficacy of PCI-32765 in combination with carfilzomib (Kyprolis™) with and without dexamethasone in subjects with relapsed or relapsed and refractory multiple myeloma (MM).
- Measurable disease of MM as defined by at least ONE of the following:
1. Serum monoclonal protein (SPEP) ≥1 g/dL
2. Urine M-protein ≥200 mg/24 hrs
3. Serum free light chain (SFLC): involved FLC ≥10 mg/dL (≥100 mg/L) AND abnormal kappa to lambda serum free light chain ratio
- Relapsed or relapsed and refractory MM after receiving at least 2 previous therapies, including an immunomodulator and bortezomib and had either no response or documented disease progression (according to IMWG criteria) to the most recent treatment regimen
- Adequate hematologic, hepatic, and renal function
- ECOG performance status of 0-2
Inclusion Criteria for Phase 2 Sub-study Cohort:
- Must meet all inclusion criteria defined in main study and in addition the following criteria must be met:
- Subject must have received a regimen containing carfilzomib in combination with dexamethasone as their most recent line of therapy and have:
1. Achieved less than a partial response (
2. Disease progression following an initial confirmed response of MR or better to the combination (according to IMWG response criteria).
- Subject must not have primary refractory disease
- Plasma cell leukemia, primary amyloidosis or POEMS syndrome
- Unable to swallow capsules or disease significantly affecting gastrointestinal function
- Requires anti-coagulation with warfarin or a vitamin K antagonist
- Requires treatment with strong CYP3A inhibitors
Exclusion Criteria for Phase 2 Sub-study Cohort:
- Must not meet any exclusion criteria defined in main study except for exclusion criteria "Subject must not have primary refractory disease" which is related to prior carfilzomib